Skip to content
OpenCapital
Get started

Medifast MED Proceeds From Sale And Maturity Of Available For Sale Securities

Proceeds From Sale And Maturity Of Available For Sale Securities at other companies

Automatic Data Processing, Inc. logo
Automatic Data Processing, Inc.ADP
$2.93B+133%
General Motors logo
General MotorsGM
$2.85B+167%
Edwards Lifesciences logo
Edwards LifesciencesEW
$710.1M-14.2%
ServiceNow logo
ServiceNowNOW
$1.14B-3.6%
Equitable Holdings logo
Equitable HoldingsEQH
$2.76B-38.2%
Atlantic Union Bankshares logo
Atlantic Union BanksharesAUB
$80.14M+93.7%

Other financials

Income statement

See full
Revenue$76.0M-34.3%
Gross profit$51.8M-38.6%
Operating income-$3.3M-161%
Net income-$2.1M-175%
EPS (diluted)-$0.19-171%

Balance sheet

See full
Cash & equivalents$71.5M-22.0%
Total debt$16.1M+10.2%
Total equity$197.7M-6.3%
Total assets$252.0M-10.0%

Cash flow

See full
Operating cash flow$260.0K-92.4%
CapEx$1.1M-28.0%
Free cash flow-$836.0K-144%

Valuation

See full
Market cap$121.87M-17.4%
Enterprise value$66.44M+12.8%
P/S0.4×0.0×

Profitability

See full
Gross margin70.1%-3.8pp
Operating margin-4.7%-7.0pp
Net margin-5.8%-8.1pp
FCF margin5%-9.3pp

Returns & leverage

See full
Return on equity-9.8%-20.1pp
Debt / equity0.1×0.0×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Medifast in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: Medifast’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Medifast's proceeds from sale and maturity of available for sale securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Medifast's proceeds from sale and maturity of available for sale securities?
Medifast (MED) reported proceeds from sale and maturity of available for sale securities of $29.65M in Q1 2026.
How has Medifast's proceeds from sale and maturity of available for sale securities changed year-over-year?
Medifast's proceeds from sale and maturity of available for sale securities increased by 105.0% year-over-year, from $14.46M to $29.65M.
What is the long-term trend for Medifast's proceeds from sale and maturity of available for sale securities?
Over 4 years (2021 to 2025), Medifast's proceeds from sale and maturity of available for sale securities has grown at a 99.9% compound annual growth rate (CAGR), from $5.15M to $82.09M.